Detalhe da pesquisa
1.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Breast Cancer Res
; 25(1): 39, 2023 04 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37046348
2.
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Lancet Oncol
; 21(11): 1443-1454, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33152284
3.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28600210
4.
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Cell Rep Med
; 5(3): 101435, 2024 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38417447
5.
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.
Trials
; 18(1): 561, 2017 Nov 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29179731
6.
The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective.
Trials
; 15: 379, 2014 Sep 27.
Artigo
Inglês
| MEDLINE | ID: mdl-25262026